Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 1/2019

01-03-2019 | educational

Educational no. 4: PCR-based methods

Author: Priv. Doz. Mag. Dr. Otto Zach

Published in: memo - Magazine of European Medical Oncology | Issue 1/2019

Login to get access

Summary

For decades, polymerase chain reaction (PCR) has been playing a fundamental role in hematology. Not only in diagnostics, but also in follow-up and therapeutic decision-making, PCR impacts the treatment of patients with neoplastic diseases. In this educational, commonly used PCR methods are explained. In addition, the strengths and weaknesses of PCR in the clinical setting are illustrated.
Literature
1.
Mullis KB, Faloona FA. Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. Methods Enzymol. IEEE Trans Med Imaging. 1987;155:335:50.
2.
Bench AJ. The role of molecular genetic analysis within the diagnostic haemato-oncology laboratory. Int J Lab Hematol. 2012;34(1):21–34.CrossRef
3.
Alikian M, Gale RP, Apperly JF, Foroni L. Molecular techniques for the personalized management of patients with chronic myeloid leukemia. Biomol Detect Quant. IEEE Trans Med Imaging. 2017;11:4:20.
4.
Rawer D, Borkhardt A, Wilda M, Kropf S, Kreuder J. Influence of stochastics on quantitative PCR in the detection of minimal residual disease. Leukemia. 2003;17:2527–44.CrossRef
Metadata
Title
Educational no. 4: PCR-based methods
Author
Priv. Doz. Mag. Dr. Otto Zach
Publication date
01-03-2019
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 1/2019
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-018-0460-7

Other articles of this Issue 1/2019

memo - Magazine of European Medical Oncology 1/2019 Go to the issue

comment

Demystification of palliative care. In regard to Masel and Kreye

short review

Radiochemotherapy in esophageal cancer

case report

Central nervous system-predominant Erdheim–Chester disease mimicking meningioma responding to BRAF inhibitor therapy: the importance of molecular diagnosis and targeted therapy in rare neoplastic disorders

short review

Therapeutic endoscopic strategies in early esophageal cancer and dysplastic Barrett’s epithelium

review

ESMO 2018—personal highlights

review

Current lymphoma diagnostic standards: the pathologists’ view
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits